Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Int J STD AIDS ; 19(5): 321-6, 2008 May.
Article in English | MEDLINE | ID: mdl-18482962

ABSTRACT

Shifting of hepatitis A virus (HAV) epidemiology from a high towards an intermediate endemicity pattern and use of antiretroviral therapy increased the risk of HIV/HAV coinfection in developing countries. The aim of this study was to investigate the presence of HAV markers in a cohort of HIV-infected patients from 1988 to 2004. The presence of serum anti-HAV antibodies and HAV-RNA by real-time polymerase chain reaction was investigated in 581 patients. Total anti-HAV antibodies was found in 464/581 (79.8%) patients, however, a changing epidemiologic pattern of hepatitis A among HIV-infected patients from 1988 to 2004 was observed. Among patients susceptible to HAV (n = 117), 5 (4.2%) were coinfected with HAV, all of them had IgM anti-HAV antibodies and were serum HAV-RNA-positive. The high prevalence of anti-HAV antibodies in HIV-infected patients suggests that screening tests for anti-HAV antibodies should be performed before implementation of hepatitis A vaccination, especially in those patients from endemic countries.


Subject(s)
HIV Infections/complications , Hepatitis A Vaccines/administration & dosage , Hepatitis A virus/immunology , Adolescent , Adult , Brazil/epidemiology , Child , Child, Preschool , Cohort Studies , Female , HIV Infections/virology , Hepatitis A Antibodies/blood , Hepatitis A Vaccines/therapeutic use , Hepatitis A virus/isolation & purification , Humans , Infant , Male , Middle Aged
2.
Braz J Infect Dis ; 5(2): 98-100, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11493415

ABSTRACT

Mycobacterial pseudotumor (MP) is a rare pathologic presentation of both Mycobacterium tuberculosis and non-tuberculous mycobacterial disease, hitherto reported to occur only in immunosuppressed patients with or without human immunodeficiency virus infection. This lesion shares close pathologic resemblance to certain mesenchymal neoplasms, particularly Kaposi's sarcoma (KS), from which it must be properly differentiated due to distinct prognosis and therapy. We report a case of MP obliterating the lumen of the appendix vermiformis in a 34-year-old patient who died of complications of AIDS at our hospital in Rio de Janeiro. A total of 24 cases of MP (including our patient) have been described in the literature. MP has been found especially in lymph nodes, but extranodal lesions have been described in the skin, spleen, lung, bone marrow, brain and, in our patient, the appendix vermiformis. We offer a review of the other 23 published case reports of MP in both HIV-infected and uninfected patients and discuss the pathologic features that differentiate MP from KS.


Subject(s)
AIDS-Related Opportunistic Infections/diagnosis , Appendix/microbiology , HIV Infections/complications , Mycobacterium avium-intracellulare Infection/diagnosis , Sarcoma, Kaposi/diagnosis , AIDS-Related Opportunistic Infections/microbiology , AIDS-Related Opportunistic Infections/pathology , Adult , Diagnosis, Differential , Fatal Outcome , Humans , Immunocompromised Host , Lymph Nodes/pathology , Male , Mycobacterium avium-intracellulare Infection/microbiology , Mycobacterium avium-intracellulare Infection/pathology , Sarcoma, Kaposi/microbiology , Sarcoma, Kaposi/pathology
3.
Infection ; 29(2): 99-102, 2001.
Article in English | MEDLINE | ID: mdl-11339484

ABSTRACT

A wide variety of disorders of diverse pathogenic mechanisms can trigger spinal cord dysfunction in HIV-1-infected patients. The most common such condition is HIV-1-associated myelopathy (HM) which characteristically complicates advanced HIV-1 disease in patients with low CD4 cell counts and previous AIDS-defining diagnoses. We describe an unusual presentation of HM in a previously asymptomatic patient with a relatively preserved CD4 cell count (458 cells/mm3) who was even unaware of his serological status. The patient presented with a clinically severe, slowly progressive myelopathy and could not walk unassisted. Significant neurological improvement could be obtained as rapidly as within 4 weeks after the institution of an antiretroviral combination of only two nucleoside analog HIV-1 reverse transcriptase inhibitors (zidovudine and didanosine). An HIV-1 protease inhibitor was also prescribed at that point but could only be added to intensify the regimen 3 months later, when significant neurological improvement had already been recorded. We also review the disorders reported to derange spinal cord function in previously asymptomatic HIV-1-infected patients.


Subject(s)
HIV Infections/complications , HIV-1/pathogenicity , Spinal Cord Diseases/virology , CD4 Lymphocyte Count , Disease Progression , HIV Infections/drug therapy , Humans , Male , Middle Aged , Reverse Transcriptase Inhibitors/therapeutic use , Spinal Cord Diseases/drug therapy , Spinal Cord Diseases/etiology , Treatment Outcome
4.
Scand J Infect Dis ; 33(3): 239-40, 2001.
Article in English | MEDLINE | ID: mdl-11303821

ABSTRACT

We retrospectively reviewed the effects on the erythrocyte mean corpuscular volume (MCV) of the use of stavudine-including antiretroviral regimens in both zidovudine-naive and zidovudine-experienced HIV-infected patients. Macrocytosis was commonly observed among patients on stavudine-based regimens although the MCV usually stabilized at a lower level than that observed with zidovudine.


Subject(s)
Anemia, Macrocytic/chemically induced , Anti-HIV Agents/adverse effects , Erythrocyte Indices/drug effects , HIV Infections/drug therapy , Stavudine/adverse effects , Anti-HIV Agents/therapeutic use , Cohort Studies , Female , HIV Infections/blood , Humans , Male , Retrospective Studies , Stavudine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...